Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Atara Biotherap (ATRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Zacks.com highlights: Arbor Realty Trust, Simpson Manufacturing and Atara Biotherapeutics

Zacks.com highlights: Arbor Realty Trust, Simpson Manufacturing and Atara Biotherapeutics

ABR : 8.44 (-0.82%)
SSD : 58.90 (unch)
ATRA : 27.55 (-2.48%)
3 Stocks in Focus on New Analyst Coverage

Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.

ABR : 8.44 (-0.82%)
SSD : 58.90 (unch)
ATRA : 27.55 (-2.48%)
Atara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that...

ATRA : 27.55 (-2.48%)
Atara Biotherapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that...

JPM : 112.27 (-0.36%)
ATRA : 27.55 (-2.48%)
Uptrend Call Working As Atara Biotherape Stock Rises 20.3% (ATRA)

SmarTrend identified an Uptrend for Atara Biotherape (AMEX:ATRA) on December 19th, 2017 at $15.13. In approximately 2 weeks, Atara Biotherape has returned 20.33% as of today's recent price of $18.20.

ATRA : 27.55 (-2.48%)
Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the...

JPM : 112.27 (-0.36%)
ATRA : 27.55 (-2.48%)
Atara Biotherapeutics Announces Proposed Offering of Common Stock

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that...

JPM : 112.27 (-0.36%)
ATRA : 27.55 (-2.48%)
Atara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)

- Three clinical sites for both the MATCH and ALLELE pivotal studies now open for enrollment in the U.S. -

ATRA : 27.55 (-2.48%)
Goldman Sachs and Hess slide while PepsiCo and TiVo rise

NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday:

ADTN : 19.50 (-1.02%)
PGNX : 6.04 (-4.73%)
BCEI : 28.00 (-2.78%)
PEP : 117.86 (+0.41%)
ATRA : 27.55 (-2.48%)
Atara Biotherapeutics to Host Corporate Update Conference Call on Friday, December 29, 2017, at 8:00 a.m. EST

- Company to announce FDA clearance to initiate two Phase 3 tabelecleucel clinical studies -

ATRA : 27.55 (-2.48%)
Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus (EBV) Associated Post-Transplant Lymphoproliferative Disorder (PTLD)

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that...

ATRA : 27.55 (-2.48%)
Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune diseases and serious viral infections, today...

ATRA : 27.55 (-2.48%)
Atara Biotherapeutics to Participate in Four Upcoming Investor Conferences

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune diseases and serious viral infections, today...

ATRA : 27.55 (-2.48%)
Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers

Updated ATA230 results in patients with cytomegalovirus (CMV) viremia and disease post-transplant will also be presented

ATRA : 27.55 (-2.48%)
Atara Biotherapeutics Receives Rare Pediatric Disease Designation from FDA for ATA230 for Treatment of Congenital Cytomegalovirus (CMV) Infection

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune diseases and serious viral infections, today...

ATRA : 27.55 (-2.48%)
Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190

Three patients in the study improved their Expanded Disability Status Scale (EDSS) score

ATRA : 27.55 (-2.48%)
Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS)

Enrollment to begin in Australia; U.S. sites expected to open in early 2018

ATRA : 27.55 (-2.48%)
Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis (MS)

Five of eight progressive MS patients who received the full course of autologous ATA190 experienced clinical improvements

ATRA : 27.55 (-2.48%)
Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129

-- Health Canada New Drug Submission (NDS) planned based on Phase 1 and 2 clinical results and supported by available data from anticipated MATCH and ALLELE Phase 3 studies, which are expected to be ongoing...

ATRA : 27.55 (-2.48%)
Atara Biotherapeutics Receives FDA Orphan Drug Designation for ATA230

Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and autoimmune diseases, today announced that ATA230...

ATRA : 27.55 (-2.48%)

Van Meerten Stock Picks

My 5 Favorite Mid Cap Stocks
This morning I wanted to find 5 Mid Cap stocks that had great returns over the past year and still seem to have some juice left.
KBH -1.63 , IPGP +2.02 , FSLR -2.19 , NVR -17.23 , SGMS +0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.39%) are up +0.41% at a fresh record nearest-futures high as growth optimism fuels gains in global equity markets. Gains in technology stocks are leading the overall market higher as... Read More

Chart of the Day

Chart of the Day

Audentes Therapeutcs (BOLD) is rhe Barchart Chart of the Day.  The biomedical company has a Trend Spotter buy signal, a Weighted Alpha of 174.58+ and gained 111.74% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures bounced back from Friday’s bearish USDA reports to close Tuesday with gains of 2 cents in most nearby contracts. The weekly Export Inspections report indicated just 584,389 MT of corn was shipped during the week of Jan 11. That is ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.